NCT04969861 2023-01-12
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Nektar Therapeutics
Phase 2/3 Terminated
Nektar Therapeutics
Radiation Therapy Oncology Group
Dana-Farber Cancer Institute